Role of CD44 as a marker of cancer stem cells in head and neck cancer

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 379-383

  Trapasso, Serena ^a   Allegra, Eugenia ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cancer stem cells; CD44; Head and neck squamous cell carcinoma

Indexed keywords

CELL MARKER; HERMES ANTIGEN; HYALURONIC ACID;

CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STEM CELL; DISEASE ASSOCIATION; HEAD AND NECK CANCER; HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84872223569     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S37906     Document Type: Review

References (64)

1. Koukourakis MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer. 2012;106:846-853.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-3988.
4. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-5828.
5. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946-10951.
6. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104:10158-10163.
7. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037.
8. Ho MM, Ng AV, Lam S, Hung J Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827-4833.
9. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104: 973-978.
10. Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med. 2007;36:594-603.
11. van der Windt GJ, Schouten M, Zeerleder S, Florquin S, van der Poll T. CD44 is protective during hyperoxia-induced lung injury. Am J Respir Cell Mol Biol. 2011;44:377-383.
12. Peterson LF, Wang Y, Lo MC, Yan M, Kanbe E, Zhang DE. The multifunctional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation. Leukemia. 2007;21:2010-2019.
13. Hanagiri T, Shinohara S, Takenaka M, et al. Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma. Tumour Biol. Epub August 11, 2012.
14. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39:527-579.
15. Fang XJ, Jiang H, Zhao X P, Jiang WM. The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7. BMC Cancer. 2011;11:290.
16. Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211-231.
17. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, Bernard A. CD44 contributes to T cell activation. J Immunol. 1989;143:798-801.
18. Toyama-Sorimachi N, Miyasaka M. A sulfated proteoglycan as a novel ligand for CD44. J Dermatol. 1994;21:795-801.
19. Olsson E, Honeth G, Bendahl PO, et al. CD44 isoforms are heteroge-neously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer. 2011;11:418.
20. Brown RL, Reinke LM, Damerow MS, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011;121:1064-1074.
21. Peterson RM, Yu Q, Stamenkovic I, Toole B P. Perturbation of hyaluro-nan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol. 2000;156:2159-2167.
22. Lucas MG, Green AM, Telen MJ. Characterization of the serum In(Lu)-related antigen: Identification of a serum protein related to erythrocyte p80. Blood. 1989;73:596-600.
23. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an adhesion molecule as in indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum. 1991;34:1434-1443.
24. Guo YJ, Liu G, Wang X, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994;54:422-426.
25. Van Hal NL, Van Dongen GA, Ten Brink CB, et al. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res. 1999;5:3534-3541.
26. Misra S, Ghatak S, Zoltan-Jones A, Toole B P. Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem. 2003; 278:25285-25288.
27. Osaki M, Kase S, Adachi K, Takeda A, Hashimoto K, Ito H. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol. 2004;130:8-14.
28. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296:1655-1657.
29. Graham VA, Marzo AL, Tough DF. A role for CD44 in T cell development and function during direct competition between CD44+ and CD44- cells. Eur J Immunol. 2007;37:925-934.
30. Ayroldi E, Cannarile L, Migliorati G, Bartoli A, Nicoletti I, Riccardi C. CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood. 1995;86:2672-2678.
31. Joshua B, Kaplan MJ, Doweck I, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck. 2012;34:42-49.
32. Kunishi M, Kayada Y, Yoshiga K. Down-regulated expression of CD44 variant 6 in oral squamous cell carcinomas and its relationship to regional lymph node metastasis. Int J Oral Maxillofac Surg. 1997;26:280-283.
33. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target. 2012;20:561-573.
34. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95:930-935.
35. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope. 2009;119:1518-1530.
36. Kokko LL, Hurme S, Maula SM, et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 2011;47:510-516.
37. Rajarajan A, Stokes A, Bloor BK, et al. CD44 expression in oro-pharyngeal carcinoma tissues and cell lines. PLoS One. 2012;7:e28776.
38. Carinci F, Stabellini G, Calvitti M, et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg. 2002;13:85-89.
39. Lindquist D, Ahrlund-Richter A, Tarján M, Tot T, Dalianis T. Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res. 2012;32: 153-161.
40. Fonseca I, Pereira T, Rosa-Santos J, Soares J. Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: a correlation with histological grade, pattern of stromal invasion, and cell differentiation. J Surg Oncol. 2011;76: 115-120.
41. Mostaan LV, Khorsandi MT, Sharifan SM, et al. Correlation between E-cadherin and CD44 adhesion molecules expression and cervical lymph node metastasis in oral tongue SCC: predictive significance or not. Pathol Res Pract. 2011;207:448-451.
42. Rodrigo J P, Domínguez F, Alvarez C, González M V, Herrero A, Suárez C. Clinicopathologic signifcance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 2002;118:67-72.
43. Masuda M, Kuratomi Y, Shiratsuchi H, Nakashima T, Naonobu K, Komiyama S. Decreased CD44H expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. Head Neck. 2000;22:662-665.
44. Yüce I, Bayram A, Caǧli S, Canöz O, Bayram S, Güney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol. 2011;32:141-146.
45. Uwa N, Kataoka TR, Torii I, et al. CD44 expression is related to poor prognosis of hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 2011;131:323-329.
46. de Jong MC, Pramana J, van der Wal JE, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res. 2010;16:5329-5338.
47. Sun B, Zhao S, Zhou C, Yan Q, Wang H. Detection of PD4, CD44, PCNA protein and its clinical signifcance in human laryngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;24: 817-819. Chinese.
48. Lu S, Tian J, Lv Z, et al. The probable role of tumor stem cells for lymph node metastasis in supraglottic carcinoma. Pathol Oncol Res. 2011;17:33-38.
49. Bourguignon LY, Wong G, Earle C, et al. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2012;287(39):32800-32824.
50. Allegra E, Puzzo L, Zuccalà V, et al. Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status. World J Surg Oncol. 2012;10(1):206.
51. Allegra E, Caltabiano R, Amorosi A, Vasquez E, Garozzo A, Puzzo L. Expression of BMI1 and p16 in laryngeal squamous cell carcinoma. Head Neck. Epub June 22, 2012.
52. Allegra E, Trapasso S, Sacco A, et al. CD44 sol salivary levels detected by ELISA as a diagnostic test for laryngeal carcinomas. JCST. 2012;4(10):333-334.
53. Ioachim E, Assimakopoulos D, Goussia AC, Peschos D, Skevas A, Agnantis NJ. Glycoprotein CD44 expression in benign, premalignant and malignant epithelial lesions of the larynx: an immunohistochemi-cal study including correlation with Rb, p53, Ki-67 and PCNA. Histol Histopathol. 1999;14:1113-1118.
54. Pereira LH, Adebisi IN, Perez A, et al. Salivary markers and risk factor data: a multivariate modeling approach for head and neck squamous cell carcinoma detection. Cancer Biomark. 2011;10:241-249.
55. Franzmann EJ, Reategui E P, Pereira LH, et al. Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck. 2012;34:687-695.
56. Franzmann EJ, Reategui E P, Pedroso F, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1348-1355.
57. Franzmann EJ, Reategui E P, Carraway KL, Hamilton KL, Weed DT, Goodwin WJ. Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2005;14: 735-739.
58. Spafford M F, Koch WM, Reed AL, et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by mic-rosatellite analysis. Clin Cancer Res. 2001;7:607-612.
59. Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hyper-methylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res. 2008;14:97-107.
60. Califano J, Ahrendt SA, Meininger G, Westra WH, Koch WM, Sidransky D. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res. 1996;56:5720-5722.
61. Linkov F, Lisovich A, Yurkovetsky Z, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev. 2007;16:102-107.
62. Hoffman RM. Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancer mortality. Ann Intern Med. 2012;157:JC1-JC4.
63. Allegra E, Garozzo A, Lombardo N, De Clemente M, Carey TE. Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines. Acta Otorhinolaryngol Ital. 2006;26(4):185-190.
64. Cruz MH, Sidén A, Calaf GM, Delwar ZM, Yakisich JS. The stem ness phenotype model. ISRN Oncol. 2012;2012:392647.